fluorouracil and lenalidomide

fluorouracil has been researched along with lenalidomide in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Curtiss, FR1
Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y1
Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L1

Reviews

1 review(s) available for fluorouracil and lenalidomide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for fluorouracil and lenalidomide

ArticleYear
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lenalidomide; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Survival Rate; Thalidomide; Treatment Outcome

2016

Other Studies

3 other study(ies) available for fluorouracil and lenalidomide

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
    Journal of translational medicine, 2016, 05-05, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lenalidomide; Mice; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Perfusion; Pericytes; Thalidomide; Tumor Hypoxia; Xenograft Model Antitumor Assays

2016
chemdatabank.com